Inventory

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Inventory

Inventory

Inventory consists of the following at June 30, 2017 (in thousands):

	June 30, 2017		December 31, 2016
Raw materials	$	1,612	$	—
Work in process	—		—
Finished goods	24		—
Total inventories	$	1,636	$	—

Inventory acquired prior to receipt of the marketing approval for TYMLOS was expensed as research and development expense as incurred. The Company began to capitalize the costs associated with the production of TYMLOS upon receipt of FDA approval on April 28, 2017.